Kardigan Q3 GAAP EPS of -$0.64 beats by $0.43

Kardigan reported a Q3 2026 net loss of $58.6M, down from $60.2M a year earlier, with $591.4M in cash. R&D expenses rose to $64.4M. The company completed Phase 2b trials for danicamtiv and ataciguat, expecting 2027 results. Cash runway supports Phase 3 trials. KARD added Kristin Reinke to its board.

Kardigan, Inc. (KARD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 PRESS RELEASE Kardigan Reports Third Quarter 2026 Financial Results and Recent Business Updates Completed enrollment in Cohort 2 of Phase 2b danicamtiv KINSHIP-DCM trial, topline data expected in 2Q 2027; Phase 3 enrollment underway in both cohorts Completed enrollme

Kardigan (NASDAQ:KARD) extends Phase 2 trial of ataciguat, targeting 2027 results. Study finds 27% of mild to moderate patients are fast progressors, with higher risks of valve repair and hospitalization. Cardiac dysfunction prevalent in 80% of patients. Baseline data shows valve calcium as an independent risk marker. Ataciguat's potential effects on valve and heart muscle remain under investigation.

Kardigan completed enrollment in its Phase 2b KATALYST-AV trial for ataciguat, involving 156 patients with aortic stenosis. Primary endpoint data is expected in late 2027. The company will assess disease progression at Week 24 and update Phase 3 plans in early 2027. According to a real-world analysis, cardiac damage markers correlate with worse outcomes.

Kardigan Inc. (NASDAQ:KARD) completed enrollment in its Phase 2b KATALYST-AV trial for ataciguat, enrolling 156 participants. The protocol was amended to assess aortic valve calcium at Week 48. Baseline data showed varying levels of aortic valve calcium and related conditions. Topline data is expected in late 2027. The company also presented findings from a retrospective analysis of aortic stenosis progression.

Kardigan, Inc. (KARD) filed an SEC Form 8-K — Regulation FD Disclosure. PRESS RELEASE Kardigan Completes Enrollment in Phase 2b KATALYST-AV Trial and Announces New Evidence Supporting Patient Selection and Endpoints for the Evaluation of Ataciguat in Aortic Stenosis Primary endpoint of aortic valve calcium in KATALYST-AV to be assessed at Week 48 alo